October 1, 2024

Targeted therapy may help treat moderate to severe ulcerative colitis: trial – Medical News Today

September 30, 2024

Oral colon-targeted pH-responsive polymeric nanoparticles loading naringin for enhanced ulcerative colitis therapy – Journal of Translational Medicine

September 25, 2024

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis – nejm.org

September 25, 2024

Patients With Moderate-to-Severe Ulcerative Colitis May Find Significant Relief as New Treatment Option Shows Good Results in Clinical Trial – Mount Sinai

September 25, 2024

NEJM: Results From Targeted Therapy for Ulcerative Colitis Study – Cedars-Sinai